Some cancer therapies use monoclonal antibodies (those targeting PD-1 or PD-L1) to increase the immune system’s ability to combat tumor cells, causing the interaction between PD-1 and PD-L1 to be inhibited (Ramos-Casals et al., 2020). This evidence concerns the gene PDCD1 and neoplasm.